Navigation Links
Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
Date:2/17/2009

Tumor Structure Should Be Considered in Treating NSCLC, Says Report in "The Oncologist"

DURHAM, N.C., Feb. 17 /PRNewswire/ -- A tumor's cellular structure, or histology, improves treatment decisions that may lead to improved outcomes for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a paper in the latest issue of "The Oncologist."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

The findings are based on an analysis of recent studies of the chemotherapy drug pemetrexed to treat NSCLC. "The data confirm that histology matters when treating NSCLC," says Professor Giorgio Scagliotti, M.D., of University of Turin, lead author of the new report.

Prof. Scagliotti and colleagues analyzed data from two recent phase III studies of pemetrexed for NSCLC, which accounts for about 90 percent of all lung cancers. They focused on how differences in cancer histology affect the response to treatment with pemetrexed. The histology of a cancer is its microscopic cellular structure and in NSCLC, tumors may be classified as having a "squamous" or "non-squamous" appearance.

Their analysis showed significant differences in response to pemetrexed between these two lung cancer subtypes. Specifically, pemetrexed was more effective than current forms of chemotherapy against cancers with a non-squamous histology. For these patients, pemetrexed led to significant improvements in overall survival and in survival without progressive cancer. In contrast, for patients whose cancers had the squamous histology, outcomes were similar with or without pemetrexed.

The two studies were a "frontline" trial including patients with previously untreated NSCLC and a "second-line" trial including patients with previous chemotherapy. The interaction between cancer histology and response to pemetrexed was similar in both groups of patients. Based on the results of the frontline trial, pemetrexed has been approved for initial treatment of NSCLC in Europe, Canada and the United States, in combination with cisplatin, another chemotherapy drug.

In the past, cancer histology hasn't been considered in selecting treatments for patients with NSCLC. "For more than 25 years medical oncologists have simply looked at the distinction between small-cell and non-small-cell lung cancer in making systemic treatment decisions," says Prof. Scagliotti. "This is because there has previously been no convincing evidence that the available treatments have any differential activity based on the histologic subtype of NSCLC." "On the basis of these studies, tumor histology should be carefully assessed when selecting treatment options for patients with advanced NSCLC," says Prof. Scagliotti.

The article entitled "The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies," has been published by "The Oncologist," and is freely available online at:

http://theoncologist.com/cgi/content/abstract/theoncologist.2008-0232v1

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org

Contact: Dr. Martin J. Murphy, Executive Editor: 919.402.8750, Martin.Murphy@TheOncologist.com


'/>"/>
SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Targeting the protein AEG1 impairs human liver cancer growth in mice
2. Hodgkins Survivors Prone to Breast Cancer Later
3. Social Disconnection in African American Women With Breast Cancer
4. Researchers ID Biomarker for Fatal Prostate Cancer
5. Teens with cancer present unique psychological issues
6. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Greece & Cyprus
7. New Anti-Clotting Treatment Urged for Cancer Patients
8. Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
9. Normalizing tumor vessels leaves cancer more benign
10. Womens cancer outcomes improved by surgical evaluation
11. Pediatric Hodgkins disease survivors face increased breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... Aliso Viejo, CA (PRWEB) , ... June 25, 2017 , ... ... convert any media into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains ... can add film grain for distorted looks, vignettes and blurs to single out subjects, ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/8/2017)... MCKINNEY, Texas , June 8, 2017 ... Company"), a leading developer and manufacturer of ... industry, announced today that Cressey & Company ... investment firm, has completed a growth-focused investment ... acquired a majority ownership position from selling ...
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
Breaking Medicine Technology: